Abstract
Cancer stem cells (CSC) are a subpopulation of tumor cells that have superior capacities of self-renewal, metastatic dissemination, and chemoresistance. These characteristics resemble, to some extent, the outcome of certain biological processes, including epithelial–mesenchymal transition (EMT), autophagy, and cellular stress response. Indeed, it has been shown that the stimuli that induce these processes and CSC are overlapping, and CSC and tumor cells that underwent EMT or autophagy are much alike. However, as the cross talk between CSC, EMT, autophagy, and cellular stress is further explored, these processes are also found to have an opposing role in CSC, depending on the condition and status of cells. This contextual effect is likely due to overwhelming reliance on CSC markers for their identification, and/or discrepancies in recognition of CSC as a particular cell population or cellular state. In this review, we summarize how EMT, autophagy, and cellular stress response are tied or unwound with CSC. We also discuss the current view of CSC theory evolved from the emphasis of heterogenicity and plasticity of CSC.
Keywords: Autophagy, Cancer stem cells, Cellular stress, Epithelial–mesenchymal transition, Heterogenicity, Plasticity
1. INTRODUCTION: HISTORICAL VIEW OF CANCER STEM CELLS
Increasing evidence over the past decades suggests that cancer cells are hierarchically organized within tumor, in which a subpopulation of cancer stem cells (CSC) is responsible for sustaining tumor growth.1–3 These CSC share important characteristics with normal stem cells, including self-renewal,4 differentiation capacity,5 and quiescence, which, collectively, are referred to as the “stemness” properties. The CSC hypothesis was initially proposed in the nineteenth century on the basis of observation of morphologic heterogeneity in cancers. The first solid evidence supporting the existence of CSC was found in acute myeloid leukemia (AML) in 1994 by fractionating AML cells based on their cell surface markers CD34+ CD38– using flow cytometry.6 Later, CSC were also identified in other types of tumors including breast cancer, colon cancer, glioblastoma, and head and neck squamous cell carcinoma.7–9 The principle of CSC model describes that CSC divide asymmetrically, generating undifferentiated daughter cells that remain as CSC, as well as differentiated daughter cells that compose the bulk of tumor, whereas non-CSC do not have these capacities.10 As such, it was believed that CSC are epigenetically (or genetically) and metabolically distinct from non-CSC. Because CSC subpopulation was defined as cells with cancer-initiating ability, regardless of whether or not they derive from normal stem cells, the term “tumor-initiating cells (TICs)” is sometimes preferred by researchers.
Given that the CSC subpopulation is closely associated with poor prognosis,11 their identification is of particular importance. Most CSC in a variety of malignancies have been identified by the detection of specific surface marker, such as CD133, CD44, and Oct-4, either alone or in combination.8,12,13 The intracellular proteins (such as aldehyde dehydrogenase 1),14 capability of efflux of Hoechst 33352 dye (known as side population),15 and reduced reactive oxygen species (ROS),16 have also been employed to mark the CSC. However, even though a list of markers has been linked to CSC, it is not uncommon that the putative CSC only express a few of them. Meanwhile, it remains to be determined how reliably these markers reflect the stemness of cells.
In addition to their identification, the investigation of the biological process closely associated with CSC is equally important. Among various biological processes, epithelial–mesenchymal transition (EMT), autophagy, and cellular stress response have been associated with CSC, although their effects on CSC are not in consensus. In the following sections, we review both sides of the evidence that couples/uncouples these processes with CSC and discuss the current view that regards CSC as a cellular state of a heterogeneous population of cancer cells.
2. EMERGING EVIDENCE UNLINKS CSC AND EMT
The EMT is a gene-reprogramming process that has been closely associated with several features of CSC. Regardless of whether it is driven by the environmental stimuli or other mechanisms, EMT enhances the migratory and invasive potentials of cancer cells.17–19 The induction of EMT has been linked to self-renewal and tumor-initiating capacities, which is supported by the findings that EMT transcription factors, Snail and ZEB1, repress the epithelial features and subsequently initiate the dedifferentiation in colon, gastric, breast, and liver cancers.20–30 Phenotypically, it has been demonstrated that cancer cells underwent EMT form at least 10-fold more tumor spheres.31 Moreover, several studies using the in vivo mouse breast cancer model showed that the upregulation of Snail by the induction of EMT augments the efficiency in tumor formation20,32 and that the CD24– subpopulation that is transitioned from CD24+ breast cancer cells by TGF-β-induced EMT displays superior tumor-initiating capacity.33,34 Accordingly, it is generally agreed that EMT promotes the acquisition of mesenchymal-like phenotype, simultaneously endowing CSC with the abilities to invade, metastasize, colonize, and self-renew.
Although previous studies favor the notion that EMT is a general feature of CSC,20,34–37 growing evidence suggests that cancer cells undergoing EMT may not necessarily gain stemness properties, thus uncoupling the CSC and EMT. Indeed, Ye et al employed the MMTV-PyMT promoter-driven mouse breast cancer model and showed that the Slug and Sox9, two well-known EMT transcription factors, may play different roles in mammary stem cells and breast CSC-like cells.20 Celià-Terrassa et al found that the subpopulation with mesenchymal traits is deprived in TICs and that an overexpression of Snail1 in TIC-enriched subpopulation suppresses their self-renewal and metastatic phenotype.38,39 Conversely, knockdown of Snail1 not only enhances the epithelial features but also augments the tumor-initiating capacity of TIC. Beck et al showed that, in skin papilloma, the level of Twist1 required for the tumor maintenance by promoting proliferation has minimal effect on the repression of E-cadherin and induction of EMT, implying that the mesenchymal phenotype and tumor-initiating capability are not constantly linked.40 Redmer et al and Polo et al even showed that the epithelial molecule E-cadherin is crucial for embryonic stem (ES) cell pluripotency and that the mesenchymal–epithelial transition initiates the cellular reprogramming of fibroblast to induced pluripotent stem cells.41–44 These studies thus suggest that the EMT may be dispensable during the process of CSC development. Not only is the contribution of EMT to CSC formation heavily debated but also the role of EMT in metastatic phenotype of CSC is argued. As exemplified by the study from Ocaña et al, while Prrx1 is capable of inducing EMT in embryos and cancer cells, downregulation of this transcription factor actually facilitates breast stem-like cancer cells to metastasize.45 Accordingly, it should be appropriate to consider EMT and CSC formation being two separate pathways that, nonetheless, can cross each other.
3. CONTROVERSY REMAINS BETWEEN CSC AND CELLULAR STRESS RESPONSE
Over the past decades, the majority of studies generally reach a consensus on the hypothesis of “dynamic stemness,” presuming that the stemness of CSC is inducible from the subpopulation of committed cancer cells. Due to the facts that tumors are constantly challenged by various stress and that their continuous growth requires CSC, the cellular responses to stress are assumed to have a role in the reprogramming of cancer cells into CSC. Indeed, hypoxia that often occurs as tumors outgrow the normal blood supply has been demonstrated as a strong stimulus to enhance the aggressive behavior of multiple malignancies. Accumulated studies also showed that embryonic and several pluri- or multipotent stem cells reside in a relatively hypoxic environment and that the stem-like phenotype in prostate, lung, and other types of cancers is enhanced by hypoxia.46,47 Another cellular stress that reportedly predisposes cancer cells to enhanced stem-like phenotype is the oxidative stress. Gopal et al and Saijo et al employed low dose of H2O2 in culture medium and showed that the induction of oxidative stress upregulates the Sox2 activity and certain stem-like phenotypes in breast (MCF7 and ZR751) and lung (ZR751) cancer cell lines.48,49 In addition to the hypoxic and oxidative stress, high level of replication stress is also commonly found in the CSC subpopulation. The increase in replication stress is often associated with aberrant DNA replication and cell cycle progression subsequent to the oncogene overactivation. As shown in the studies of glioma and colorectal cancers, the tumor cells are heterogeneous in the amount of constitutive replication stress, and the level of which is higher in the subset of CSC than non-CSC. Consistently, a number of studies demonstrated that CSC are inherently equipped with robust replication stress and DNA damage response, allowing these cells to tolerate high level of replication stress. Taken together, these studies suggest that cellular stress and the response may directly contribute to, or at least be implicated in, the process of CSC development.
Although an association between stress response with CSC has been demonstrated, it is still puzzling that cellular stress, which is potentially cytotoxic, exerts a promotive effect on CSC development. Specifically, it is unclear why and how CSC harbor high level of replication stress, which essentially opposes DNA replication and cell proliferation. Notably, McGrail et al recently used systemic-level approaches and found that CSC are featured with gene signature defective in replication stress response and that such defects in replication stress response rewrite nonmalignant cells into a CSC-like state.50 Parkes et al also showed that deficiency in genes associated with DNA repair in S phase promote cancer cells transitioning toward CSC.50,51 These data, along with several lines of evidence, thus provide a solid link between replication stress response defects and cancer stemness. Likewise, Polewski et al showed that the deregulation of SLC7A11, a catalytic subunit of electroneutral transporter that functions as an ROS scavenger, increases the level of endogenous ROS and enhances the CSC phenotype.52 Accordingly, CSC may carry certain defective cellular stress response, and their stemness phenotypes are possibly the consequence of such inherent deficiency.
4. CONTEXTUAL DEPENDENCY COMPLICATES THE RELATIONSHIP BETWEEN CSC AND AUTOPHAGY
Autophagy is a lysosomal degradation pathway originally recognized as a response to nutrient deprivation and starvation. Autophagy is increased in senescent cells, which, however, can be interpreted as either a cause or a consequence of senescence.
Since autophagy has been considered as a sign of senescent cells, the observation that autophagy is upregulated and required for the maintenance of CSC is intriguing. Indeed, as shown in the studies of CSC enriched from breast, pancreatic, liver, osteosarcoma, ovarian, and glioblastoma cancers, targeting the components of autophagy negatively impacts the self-renewal capacity and the expression of stemness markers.53 Molecularly, the autophagy is linked to EGFR/Stat3, TGF-β/Smad, and STAT3/JAK2/IL-6 pathways, and the signaling of which is interrupted by disruption of autophagy, ultimately leading to a decrease in tumorigenicity of breast cancer-stem like cells.54–56 Peng et al showed that Forkhead Box A2 (FOXA2) is overexpressed in ovarian cancer stem-like cells, thus serving as a CSC marker of this cancer type and that knockdown of autophagy not only decreases the level of FOXA2 but also reduces their self-renewal ability.57 More recently, FOXO3, a mediator of the transcription of several autophagy-related genes, is shown to be required for sustaining the leukemia-initiating cells,58 although an opposite role of FOXO3 in CSC is also demonstrated in multiple malignancies.59–62 Sharif et al also found that the perturbation in basal autophagy decreases the stemness and promotes the differentiation of teratocarcinoma cells, which are highly malignant totipotent stem-like cancer cells.63 These studies suggest that the effect of autophagy on CSC is context dependent, with distinct and perhaps opposite roles in different stages of CSC development.
5. CURRENT VIEW OF CSC
5.1. CSC/non-CSC transition states: it is more than binary
Accumulated from years of studies, including those mentioned previously, the current view of CSC is updated. The concept of CSC states has evolved from a binary to a continuum, which includes intermediate CSC that exhibit partial stemness and differentiated phenotypes. This CSC/non-CSC continuum in cell phenotypes reflects the extra- and intracellular cues that simultaneously activate several dedifferentiation and differentiation-associated processes, and thus, cells can be in the middle of phenotypic transitioning due to their differential response to diverse stimuli. Indeed, as shown in the study exploiting androgen analog to enrich prostate cancer stem/progenitor population, cells that co-express stem cell-like markers CD44 and/or α2β1-integrin, as well as basal–luminal markers p63, CK5/14, and CK8/18, are detected. These cells exhibit an intermediate phenotype between basal and secretory cells of prostate epithelium and are able to self-renew or acquire a more differentiated phenotype after injuries.64–68 Another study analyzing the generation of leukemia stem cells by introducing MLL-Af9 fusion protein into myeloid cells also identified abnormal hybrid cells that have features of both stem cells and more differentiated cells.69,70 Experimentally, it is not surprising to find that the expression of several CSC markers (such as CD133, CD44, and Nanog) at single-cell level as revealed by flow cytometry often shows a single population in relatively normal distribution, instead of bimodal distribution that clearly specifies CSC vs non-CSC subpopulations.71–73 Therefore, rather than a distinguished subpopulation of cancer cells, it may be more relevant to consider CSC as a state or process by which cancer cells gain certain malignant characteristics, including enhanced tumorigenicity, chemoresistance, and metastasis.
5.2. CSC entity: it is a pool of multifunctional and interdependent cells
Another update of CSC concept, being two sides of a coin with CSC/non-CSC continuum, is that CSC refers to an entity that encompass a group of multifunctional and interdependent cells. Phenotypic heterogeneity within pluripotent ES cells, multipotent adult stem cells, and CSC of various origins has been characterized in numerous studies.74–79 Such coexistence of multiple cellular states within stem cells and CSC population was previously presumed to be the consequence of differentiation of CSC. Notably, studies of mice ES cells showed that Nanog is heterogeneously expressed, and similar Nanog distribution would be unavoidably reestablished even after repetitive cell sorting and purification.80,81 Likewise, combining the use of media that has been proven effective to enrich CSC subpopulation with flow cytometry–based cell sorting nonetheless fails to maintain CSC at a high ratio.75,82 These evidences suggest that CSC is a pool of cells that are in a dynamical equilibrium of different cellular states through reversible interconversion. Perhaps, CSC in intermediate state is important to maintain the stemness of CSC pool as a whole by releasing signaling factors or forming part of the tumor microenvironment known as niche. In support of the notion that CSC is an entity that comprises cells in different states or with varying properties, Dieter et al employed molecular tracking strategy and were able to categorize TICs of human colon cancers into three different functional types, including extensively self-renewing long-term TIC (LT-TIC), tumor transient amplifying cells (T-TACs), and delayed contributing TIC (DC-TIC).83 Importantly, different types of cells separately predominate tumor formation or metastases but collaboratively sustain the whole population of TIC. Therefore, CSC should be a pool of cells featured with functionally diverse properties that are crucial for their existence.
In conclusion, expanding the understanding of CSC population reconciles the clonal evolution “stochastic” and the CSC “hierarchical” models, allowing us to appreciate that these two models may not be mutually exclusive but actually are interrelated. Indeed, the demonstrations of heterogenicity and plasticity of CSC population derived from their ability to reprogram and revert between CSC and non-CSC refine our view of CSC. This insight rationalizes the observation that certain biological processes, including EMT and autophagy, may have dual effects on CSC. Moreover, the evidence that certain stemness-associated transcription factors, such as Nanog, Oct4, or c-Myc, fluctuate between low and high expression levels within CSC population suggests that CSC cannot be defined by a rigid phenotype.79,84–88 These updates bring into a new perspective that the state of CSC/non-CSC is a continuum in transition and the entity of CSC may contain diverse cell types of subclones. Bearing these concepts in mind, CSC population in a given study may not necessarily be the culprit for all of cancer initiation, metastatic dissemination, chemoresistance, and disease recurrence or relapse. Future studies focus on reverting cancer cells in CSC state should hold great therapeutic implications.
Footnotes
Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
REFERENCES
- 1.Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 201413497–512 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 201414275–91 [DOI] [PubMed] [Google Scholar]
- 3.Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 20088755–68 [DOI] [PubMed] [Google Scholar]
- 4.Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 201212133–43 [DOI] [PubMed] [Google Scholar]
- 5.Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001414105–11 [DOI] [PubMed] [Google Scholar]
- 6.Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 20031003983–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ghiaur G, Gerber J, Jones RJ. Concise review: cancer stem cells and minimal residual disease. Stem Cells 20123089–93 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Marsden CG, Wright MJ, Pochampally R, Rowan BG. Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 2009590363–75 [DOI] [PubMed] [Google Scholar]
- 9.Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977197461–3 [DOI] [PubMed] [Google Scholar]
- 10.Dick JE. Stem cell concepts renew cancer research. Blood 20081124793–807 [DOI] [PubMed] [Google Scholar]
- 11.Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011171086–93 [DOI] [PubMed] [Google Scholar]
- 12.Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008144085–95 [DOI] [PubMed] [Google Scholar]
- 13.Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol 20082143–9 [DOI] [PubMed] [Google Scholar]
- 14.Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 20071555–67 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 19961831797–806 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chang CW, Chen YS, Chou SH, Han CL, Chen YJ, Yang CC, et al. Distinct subpopulations of head and neck cancer cells with different levels of intracellular reactive oxygen species exhibit diverse stemness, proliferation, and chemosensitivity. Cancer Res 2014746291–305 [DOI] [PubMed] [Google Scholar]
- 17.Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell 201425563–73 [DOI] [PubMed] [Google Scholar]
- 18.Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol 200113349–55 [DOI] [PubMed] [Google Scholar]
- 19.Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 20078519–29 [DOI] [PubMed] [Google Scholar]
- 20.Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015525256–60 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, et al. Microrna-146a directs the symmetric division of snail-dominant colorectal cancer stem cells. Nat Cell Biol 201416268–80 [DOI] [PubMed] [Google Scholar]
- 22.He H, Chen W, Wang X, Wang C, Liu F, Shen Z, et al. Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci 20121031296–303 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011141279–91, 291.e15 [DOI] [PubMed] [Google Scholar]
- 24.Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Plos One 20105e12445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009111487–95 [DOI] [PubMed] [Google Scholar]
- 26.Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009692400–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, et al. The transcription factor ZEB1 (deltaef1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007266979–88 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.De Craene B, Gilbert B, Stove C, Bruyneel E, van Roy F, Berx G. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 2005656237–44 [DOI] [PubMed] [Google Scholar]
- 29.Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004107775–84 [DOI] [PubMed] [Google Scholar]
- 30.Roy HK, Iversen P, Hart J, Liu Y, Koetsier JL, Kim Y, et al. Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: modulation of apoptosis, proliferation, and fractal dimension. Mol Cancer Ther 200431159–65 [PubMed] [Google Scholar]
- 31.Lu Y, Liu L, Luan S, Xiong J, Geng D, Yin B. The diagnostic value of texture analysis in predicting WHO grades of meningiomas based on ADC maps: an attempt using decision tree and decision forest. Eur Radiol 2019291318–28 [DOI] [PubMed] [Google Scholar]
- 32.Meyer IS, Jungmann A, Dieterich C, Zhang M, Lasitschka F, Werkmeister S, et al. The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction. EMBO Mol Med 201791279–93 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Baulida J, García de Herreros A. Snail1-driven plasticity of epithelial and mesenchymal cells sustains cancer malignancy. Biochim Biophys Acta 2015185655–61 [DOI] [PubMed] [Google Scholar]
- 34.Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. Plos One 20083e2888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 201416488–94 [DOI] [PubMed] [Google Scholar]
- 36.Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, et al. Slug and sox9 cooperatively determine the mammary stem cell state. Cell 20121481015–28 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008133704–15 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Seton-Rogers S. Metastasis: dynamic interactions. Nat Rev Cancer 201212378. [DOI] [PubMed] [Google Scholar]
- 39.Celià-Terrassa T, Meca-Cortés O, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 20121221849–68 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, Delafaille S, et al. Different levels of twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 20151667–79 [DOI] [PubMed] [Google Scholar]
- 41.Redmer T, Diecke S, Grigoryan T, Quiroga-Negreira A, Birchmeier W, Besser D. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBO Rep 201112720–6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010764–77 [DOI] [PubMed] [Google Scholar]
- 43.Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010751–63 [DOI] [PubMed] [Google Scholar]
- 44.Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 20121511617–32 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer prrx1. Cancer Cell 201222709–24 [DOI] [PubMed] [Google Scholar]
- 46.Bae KM, Dai Y, Vieweg J, Siemann DW. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. Am J Cancer Res 201661078–88 [PMC free article] [PubMed] [Google Scholar]
- 47.Iida H, Suzuki M, Goitsuka R, Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 20124071–9 [DOI] [PubMed] [Google Scholar]
- 48.Gopal K, Gupta N, Zhang H, Alshareef A, Alqahtani H, Bigras G, et al. Oxidative stress induces the acquisition of cancer stem-like phenotype in breast cancer detectable by using a sox2 regulatory region-2 (SRR2) reporter. Oncotarget 201673111–27 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Saijo H, Hirohashi Y, Torigoe T, Horibe R, Takaya A, Murai A, et al. Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress. Oncotarget 2016750043–56 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.McGrail DJ, Lin CC, Dai H, Mo W, Li Y, Stephan C, et al. Defective replication stress response is inherently linked to the cancer stem cell phenotype. Cell Rep 2018232095–106 [DOI] [PubMed] [Google Scholar]
- 51.Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. J Natl Cancer Inst 2017109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev 2017261236–46 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci 201819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Yeo SK, Wen J, Chen S, Guan JL. Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/stat3 and tgfβ/Smad signaling. Cancer Res 2016763397–410 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Maycotte P, Jones KL, Goodall ML, Thorburn J, Thorburn A. Autophagy supports breast cancer stem cell maintenance by regulating IL6 secretion. Mol Cancer Res 201513651–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 20111081397–402 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Peng Q, Qin J, Zhang Y, Cheng X, Wang X, Lu W, et al. Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J Exp Clin Cancer Res 201736171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010463676–80 [DOI] [PubMed] [Google Scholar]
- 59.Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res 2015751423–32 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Ning Y, Luo C, Ren K, Quan M, Cao J. FOXO3A-mediated suppression of the self-renewal capacity of sphere-forming cells derived from the ovarian cancer SKOV3 cell line by 7-difluoromethoxyl-5,4’-di-n-octyl genistein. Mol Med Rep 201491982–8 [DOI] [PubMed] [Google Scholar]
- 61.Sunayama J, Sato A, Matsuda K, Tachibana K, Watanabe E, Seino S, et al. Foxo3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity. Stem Cells 2011291327–37 [DOI] [PubMed] [Google Scholar]
- 62.Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, et al. The role of PTEN/akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009106268–73 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Sharif T, Auger C, Bronner C, Alhosin M, Klein T, Etienne-Selloum N, et al. Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like cell. Invest New Drugs 201129239–47 [DOI] [PubMed] [Google Scholar]
- 64.Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 2019565312–7 [DOI] [PubMed] [Google Scholar]
- 65.Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015348880–6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol 201315338–44 [DOI] [PubMed] [Google Scholar]
- 67.Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT, Misteli T. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev Cell 200610105–16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004432396–401 [DOI] [PubMed] [Google Scholar]
- 69.Faber J, Armstrong SA. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res 2007678425–8 [DOI] [PubMed] [Google Scholar]
- 70.Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 200610257–68 [DOI] [PubMed] [Google Scholar]
- 71.Yu J, Wang S, Zhao W, Duan J, Wang Z, Chen H, et al. Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel α2δ1 subunit-mediated chemotherapy resistance in small-cell lung cancer. Clin Cancer Res 2018242148–58 [DOI] [PubMed] [Google Scholar]
- 72.Lim W, Kim HE, Kim Y, Na R, Li X, Jeon S, et al. Association between cancer stem cell-like properties and epithelial-to-mesenchymal transition in primary and secondary cancer cells. Int J Oncol 201649991–1000 [DOI] [PubMed] [Google Scholar]
- 73.Wangpu X, Yang X, Zhao J, Lu J, Guan S, Lu J, et al. The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear β-catenin and CD44. Oncotarget 2015633893–911 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Kumar RM, Cahan P, Shalek AK, Satija R, DaleyKeyser A, Li H, et al. Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature 201451656–61 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Peng T, Qinghua M, Zhenning T, Kaifa W, Jun J. Long-term sphere culture cannot maintain a high ratio of cancer stem cells: a mathematical model and experiment. Plos One 20116e25518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 20111086468–73 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Lorico A, Rappa G. Phenotypic heterogeneity of breast cancer stem cells. J Oncol 20112011135039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Graf T, Stadtfeld M. Heterogeneity of embryonic and adult stem cells. Cell Stem Cell 20083480–3 [DOI] [PubMed] [Google Scholar]
- 79.Hayashi K, de Sousa Lopes SMC, Tang F, Lao K, Surani MA. Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states. Cell Stem Cell 20083391–401 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, et al. Nanog safeguards pluripotency and mediates germline development. Nature 20074501230–4 [DOI] [PubMed] [Google Scholar]
- 81.Singh AM, Hamazaki T, Hankowski KE, Terada N. A heterogeneous expression pattern for Nanog in embryonic stem cells. Stem Cells 2007252534–42 [DOI] [PubMed] [Google Scholar]
- 82.Mo J, Sun B, Zhao X, Gu Q, Dong X, Liu Z, et al. The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines. Melanoma Res 201323254–63 [DOI] [PubMed] [Google Scholar]
- 83.Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 20119357–65 [DOI] [PubMed] [Google Scholar]
- 84.Abranches E, Guedes AM, Moravec M, Maamar H, Svoboda P, Raj A, et al. Stochastic NANOG fluctuations allow mouse embryonic stem cells to explore pluripotency. Development 20141412770–9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Radzisheuskaya A, Chia Gle B, dos Santos RL, Theunissen TW, Castro LF, Nichols J, et al. A defined Oct4 level governs cell state transitions of pluripotency entry and differentiation into all embryonic lineages. Nat Cell Biol 201315579–90 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Trott J, Hayashi K, Surani A, Babu MM, Martinez-Arias A. Dissecting ensemble networks in ES cell populations reveals micro-heterogeneity underlying pluripotency. Mol Biosyst 20128744–52 [DOI] [PubMed] [Google Scholar]
- 87.Sustáčková G, Legartová S, Kozubek S, Stixová L, Pacherník J, Bártová E. Differentiation-independent fluctuation of pluripotency-related transcription factors and other epigenetic markers in embryonic stem cell colonies. Stem Cells Dev 201221710–20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Kalmar T, Lim C, Hayward P, Muñoz-Descalzo S, Nichols J, Garcia-Ojalvo J, et al. Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. Plos Biol 20097e1000149. [DOI] [PMC free article] [PubMed] [Google Scholar]
